LT5372B - New enterosorbent - Google Patents
New enterosorbent Download PDFInfo
- Publication number
- LT5372B LT5372B LT2006003A LT2006003A LT5372B LT 5372 B LT5372 B LT 5372B LT 2006003 A LT2006003 A LT 2006003A LT 2006003 A LT2006003 A LT 2006003A LT 5372 B LT5372 B LT 5372B
- Authority
- LT
- Lithuania
- Prior art keywords
- shungite
- enterosorbent
- zeolite
- carbon
- zfcs
- Prior art date
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000010457 zeolite Substances 0.000 claims abstract description 26
- 239000002594 sorbent Substances 0.000 claims abstract description 21
- 229910021536 Zeolite Inorganic materials 0.000 claims abstract description 18
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000011435 rock Substances 0.000 claims abstract description 9
- 239000002245 particle Substances 0.000 claims abstract description 6
- 238000007885 magnetic separation Methods 0.000 claims abstract description 3
- 238000003801 milling Methods 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 11
- 239000008213 purified water Substances 0.000 claims description 4
- 239000007903 gelatin capsule Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 6
- 239000011707 mineral Substances 0.000 abstract description 6
- 239000002775 capsule Substances 0.000 abstract description 4
- 235000015872 dietary supplement Nutrition 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 239000001828 Gelatine Substances 0.000 abstract description 2
- 230000037396 body weight Effects 0.000 abstract description 2
- 229920000159 gelatin Polymers 0.000 abstract description 2
- 235000019322 gelatine Nutrition 0.000 abstract description 2
- 238000001179 sorption measurement Methods 0.000 description 9
- 235000015099 wheat brans Nutrition 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 4
- 229910003472 fullerene Inorganic materials 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- -1 rare ones Chemical compound 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 208000003508 Botulism Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- IXHOXXFTTQTNQS-UHFFFAOYSA-N [Ca].[Na].[K] Chemical compound [Ca].[Na].[K] IXHOXXFTTQTNQS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000002638 heterogeneous catalyst Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000009774 resonance method Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 231100000701 toxic element Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Pareiškiamas išradimas priklauso ekologiškai kenksmingų medžiagų enterosorbentams, kaip svarbiai žmogaus racionui maisto papildų grupei, ir būtent enterosorbentams gamtinių mineralų ceolito ir šungito pagrindu.The present invention relates to enteric sorbents of ecologically harmful substances as an important part of the diet of human dietary supplements, and in particular to zeolite and shungite of natural minerals.
Enterosorbentų šiandien gaminama gausybė. Tad ir „klasikiniai“ enterosorbentai aktyvintosios anglies pagrindu, ir sorbentai sintetinio amorfinio titnago, molžemio, fosfatų ir aliumosilikatų pagrindu, įskaitant dirbtinius ceolitus (fosfaliugelis, smekta ir kt.), o taip pat didelė preparatų grupė celiuliozės pagrindu (MKC, Polifepan ir kt.). Bet ir net tokio gerų ir įvairių preparatų gausumo fone enterosorbentai ir maisto papildai, pirmą kartą sukurti gamtinių ceolitų pagrindu (Litovit serija, gamintojas MGF NOV, Novosibirskas <http://argo.5566.ru/bad_litovit.php>) ir kalnų uolienos šungito pagrindu (Enterosorbentas FCS) (E.V.Osipov, H.Kondratavičius, S.E.Osipov. Žinomo sorbento panaudojimas kaip enterosorbento FCS. Paraiška LT 2006 002, 2006-01-04) išsiskiria ne tiek pigumu, kiek saugumu, efektyvumu ir universalumu. Jeigu ceolitas - „tik“ molekulinis filtras ir mineralų praturtintojas, tai FCS vandenyje tirpių kompleksų gamtinių fulerenų pagrindu dėka yra daugiau negu paprastas gamtinis sorbentas (E.V.Osipov, H.Kondratavičius, S.E.Osipov. Molecular Nanotechnology and Medicine: Natūrai Fullerene-based Water-soluble Molecular Complexes from Shungite Rocks. lst Conference on Advanced Nanotechnology. October 22-27, 2004, Washington DC, http://foresight.org/Conferences/AdvNano2004/Abstracts/Osipov/index.html). Tolesni mūsų tyrimai parodė, kad šie sorbentai vienas kitą puikiai papildo vandens valymo ir mineralizavimo filtruose (O.A.PMCteB. UlyHrHT - BeuHtiH xpaHHTejit 3/topoBBB. Μ-0Π6, JĮhjib, 2001 r.), su tuo pačiu pasisekimu gali papildyti vienas kitą kaip „sveikatos ir ilgaamžiškumo milteliai“, panašūs į mumijo, tas pats hipotetinis ateities maisto papildas, kuris pagal japonų mokslininkų prognozes galės mažiausiai penkiais metais prailginti kiekvieno žmogaus gyvenimo trukmę.Enterosorbents are produced in abundance today. Thus, both "classic" activated carbon sorbents and sorbents based on synthetic amorphous flint, alumina, phosphate and aluminosilicates, including artificial zeolites (phosphallugel, smecta, etc.), as well as a large cellulose-based formulation (MKC, Polifepan et al. ). But even with such an abundance of good and varied preparations, enterosorbents and nutritional supplements first developed on the basis of natural zeolites (Litovit series, manufactured by MGF NOV, Novosibirsk <http://argo.5566.ru/bad_litovit.php>) and mountain rock shungite (Enterosorbent FCS) (EVOsipov, H.Kondratavičius, SEOsipov. The use of a known sorbent as Enterosorbent FCS. Application LT 2006 002, 2006-01-04) is distinguished not so much by cheapness, but by safety, efficiency and versatility. If the zeolite is "only" a molecular filter and an enrichment of minerals, FCS is more water-soluble complexes based on natural fullerenes than ordinary natural sorbent (EVOsipov, H.Kondratavičius, SEOsipov. Molecular Nanotechnology and Medicine: Fullerene-based Water-soluble Molecular Complexes from Shungite Rocks .stst Conference on Advanced Nanotechnology. October 22-27, 2004, Washington DC, http://foresight.org/Conferences/AdvNano2004/Abstracts/Osipov/index.html). Further research has shown that these sorbents complement each other perfectly in water purification and mineralization filters (OAPMCteB. UlyHrHT - BeuHtiH xpaHHTejit 3 / topoBBB. Μ-0Π6, Jhjib, 2001), with the same success as “ health and longevity powder ”, similar to mummy, the same hypothetical future dietary supplement that Japanese scientists predict will extend everyone's life expectancy by at least five years.
Artimiausias pagal techninę esmę ir bendrus požymius pareiškiamam enterosorbentui yra FCS enterosorbentas fulerenų-anglies-titnago pagrindu (E.V.Osipov, H.Kondratavičius, S.E.Osipov. Žinomo sorbento panaudojimas kaip enterosorbento FCS. Paraiška LT 2006 002, 2006-01-04), kuriame dispersinė fazė (fulerenus turinti šungito anglis ~ 1/3 masės) tolygiai paskirstyta nanodalelių pavidalu dispersinėje terpėje (silikatai ~ 2/3 masės, kurių 80 % sudaro silicio dioksidas). Todėl sorbentas jungia savyje ne tik farmakologines anglies savybes, bet ir plačiai žinomas fulerenų ir titnago sveikatinančias savybes.The closest to the technical merits and general characteristics of the claimed enterosorbent is the FCS enteric sorbent based on fullerenes-carbon-flint (EVOsipov, H.Kondratavičius, SEOsipov. Use of a known sorbent as the enterosorbent FCS. Application EN 2006 002, 2006-01-04) phase (fullerene-containing shungite carbon ~ 1/3 wt.) evenly distributed in nanoparticulate dispersion medium (silicates ~ 2/3 wt. 80% silica). Therefore, the sorbent combines not only the pharmacological properties of carbon, but also the well-known health properties of fullerenes and flint.
Bet FCS sorbcijos laipsnis, veikiant toksinėms medžiagoms, žemesnis negu kai kurių gamtinių ceolitų, o tai yra pagrindinis prototipo trūkumas. Pareiškiamo išradimo tikslas yra minėto trūkumo pašalinimas, o būtent jo sorbcinių savybių efektyvumo padidinimas.But the degree of FCS sorption to toxic substances is lower than that of some natural zeolites, which is a major disadvantage of the prototype. The object of the present invention is to eliminate the aforementioned disadvantage, namely to increase the efficiency of its sorption properties.
Užsibrėžtas tikslas pasiekiamas tuo, kad ZFCS (ceolitas + FCS) gaminamas iš kalnų uolienos šungito, pirma atliekant šungito su 27-32 % anglies koncentracija radiometrinį magnetinį praturtinimą, atrenkant 33±1 % anglies turintį šungitą, atliekamas magnetinis separavimas, naudojant mažesnes negu 1 ųm dydžio daleles, kurios turi 33±1 % anglies, be to, šungito smulkinimo pradžioje pridedamas gamtinis ceolitas santykiu 1:1, ir mišinys smulkinamas vientisame technologiniame procese. Ceolito ir šungito mišinys patalpinimas į kietas želatinos kapsules, kurios (patekus per skrandį į organizmą 0,01 g dozėmis 1 kg kūno masės per parą) užgeriamos išvalytu tuo pačiu sorbentų vandeniu.The objective is achieved by the production of ZFCS (zeolite + FCS) from mountain rock shungite by first magnetic resonance enrichment of shungite with a carbon content of 27-32%, selenium containing 33 ± 1% carbon, using less than 1 µm. particles containing 33 ± 1% carbon, in addition to the addition of natural zeolite in a 1: 1 ratio at the beginning of the shungite crushing, and crushing the mixture in a single technological process. The mixture of zeolite and shungite is filled into hard gelatine capsules, which (administered via the stomach at a dose of 0.01 g / kg body weight / day) are taken in the same purified sorbent water.
Pirmas pareiškiamo enterosorbento skiriamasis požymis, lyginant su prototipu, yra tik tam tikrų gamtinių ceolitų panaudojimas. Ceolitų yra žinoma daugybė, ir jie sudaro ypatingą heterogeninių katalizatorių klasę. Tai yra tvarkingos korinės struktūros, kurios narvelių dydis sulyginamas su daugybės organinių molekulių dydžiais, aliumosilikatai. Juos dar vadina molekulių sietais. Ceolitų vidurkinė sudėtis %: SiO2 - 72,68; TiO2 - 0,16; A12C>3 - 10,81; Fe2O3 - 2,56; CaO - 1,17; MgO - 0,22; MnO - 0,08; Na2O - 1,44; K2O - 3,69; SO3 - mažiau 0,01; vanduo - 6,38. Pagal cheminę sudėtį ceolitai priskiriami aukštai silikuotam tipui, o pagal katijonų rinkinį - kalcio-natrio-kalio tipui. Jie priklauso mineralinei žaliavai, pasižyminčiai aukštu atsparumu temperatūrai ir rūgštims su 92-93 % struktūros išsilaikymo laipsniu. Ceolito pasirinkimo ZFCS enterosorbento gamybai svarbiausias pasirinkimo kriterijus yra mineralas su per šimtmečius žmogaus patikrintomis sveikatinančiomis savybėmis, pavyzdžiui, ceolitas iš Darasuno kurorto apylinkių (Užbaikalė).The first distinguishing feature of the claimed enterosorbent compared to the prototype is the use of only certain natural zeolites. Zeolites are known in large numbers and form a special class of heterogeneous catalysts. These are aluminosilicates of a neat cellular structure whose cage size is comparable to that of many organic molecules. They are also called molecular sieves. Zeolites% average composition: SiO 2 to 72.68; TiO 2 - 0.16; Al 2 C 3 - 10.81; Fe 2 O 3 - 2.56; CaO - 1.17; MgO - 0.22; MnO = 0.08; Na 2 O = 1.44; K 2 O - 3.69; SO 3 - less than 0.01; water 6.38. According to their chemical composition, zeolites are classified as high silicate type and according to cation set as calcium-sodium-potassium type. They belong to a mineral raw material with high temperature and acid resistance with a 92-93% degree of structure retention. The most important criterion for the selection of zeolite for the production of ZFCS enterosorbent is a mineral with centuries of human-proven health properties, such as zeolite from the Darasun resort area (Quebec).
Abi uolienos, iš kurių gaminamas ZFCS enterosorbentas, gaunamos iš nuo seno garsių kurortų regionų (šungitas iš Karelijos, kur ant šungito pagrindo išsidėstęs prieš 300 metų įkurtas kurortas „Marcialiniai vandenys“, o ceolitas iš Čitos srities, iš prieš 200 metų įkurto kurorto „Darasun“ regiono). Visiškai išaiškinta, kad gydančiu vandenį paverčia išsiskiriančios į vandenį mineralų mikropriemaišos. Todėl būgštavimai dėl atokių pasekmių nuo mikropriemaišų, išsiskyrusių į vandenį iš šių dviejų uolienų, neturi jokio pagrindo. Parinktas ceolitas absoliučiai netoksiškas, nesirezorbuoja ir nesikaupia virškinimo trakte, kaip po vienkartinio, taip ir po pakartotinio vartojimo, ir leidžiamas parenteraliniam vartojimui, t.y. patalpinant sorbentą į virškinimo trakto vidų. Kadangi ceolitai turi savybę sulaikyti vandenį ir užtikrina prolonguotą veikimą, užpildant ertmes amoniu, katijonais, mikroelementais, tarp jų ir retais, - tai ilgo maistinių elementų užlaikymo organizme, jų pilnaverčio įsisavinimo su laipsnišku išskyrimu klausimai išsisprendžia. Ir kaip rezultatas: enterosorbentas ZFCS išsiskiria katalizatoriaus, selektyvios jonų apykaitos ir pasirinktinės sorbcijos savybėmis, kurios leidžia pašalinti iš organizmo mažos molekulinės masės kenksmingus junginius (metanas, amoniakas, sieros vandenilis, toksinai ir kt.), o taip pat perteklinius metalų jonus; jis surenka ir šalina iš organizmo dujas, rūgimo, puvimo ir medžiagų apykaitos produktus.Both rocks that make ZFCS enterosorbent come from long-established resort regions (Shungite from Karelia, where the Marian Waters were founded 300 years ago, and Zeolite from the Chita area, 200 years ago from Darasun) "Region). It is fully explained that the micro-impurities of minerals released into the water are converted into healing water. Therefore, fears about the remote consequences of micro-impurities dispersed in water from these two rocks have no basis. The selected zeolite is absolutely nontoxic, does not resorb and does not accumulate in the gastrointestinal tract, both after single and repeated administration, and is allowed for parenteral administration, i.e. placing the sorbent inside the gastrointestinal tract. Because zeolites have the ability to retain water and provide prolonged action by filling cavities with ammonia, cations, trace elements, including rare ones, the issue of long nutrient retention in the body is solved by its gradual uptake. And as a result, the ZFCS enterosorbent is characterized by its catalytic, selective ion exchange and selective sorption properties, which remove harmful compounds (methane, ammonia, hydrogen sulfide, toxins, etc.) as well as excess metal ions from the body; it collects and removes gas, fermentation, decay and metabolic products from the body.
Antras pareiškiamo enterosorbento skiriamasis požymis, lyginant su prototipu, yra jo adsorbcinių galimybių išplėtimas optimalaus santykio tarp ceolito ir FCS sąskaita. Todėl enterosorbentas ZFCS ne tik nepraranda anglies ir gamtinių farmakologinių savybių (E.V.Osipov, H.Kondratavičius, S.E.Osipov. Žinomo sorbento panaudojimas kaip enterosorbento FCS. Paraiška LT 2006 002, 2006-01-04), bet ir žymiai sustiprina titnago sudėtinę dalį ceolito sąskaita ir įgauna kitas aukščiau nurodytas jo unikalias savybes. Enterosorbentas ZFCS jungia savyje specialiai parinktą sudėtį, kurios ingredientai sustiprina ir maksimaliai papildo vienas kito sveikatinančias savybes santykiu 1:1. Kitais santykiais pradeda dominuoti tik komponento su didesne koncentracija savybės.The second distinguishing feature of the claimed enterosorbent compared to the prototype is the extension of its adsorbent capacity at the expense of the optimum ratio between zeolite and FCS. Therefore, ZFCS enterosorbent not only loses its carbon and natural pharmacological properties (EVOsipov, H. Kondratavičius, SEOsipov. Use of a known sorbent as FCS enteric sorbent. Application EN 2006 002, 2006-01-04), but also significantly strengthens the flint constituent at the expense of zeolite. and acquires its other unique qualities above. ZFCS Enterosorbent combines a specially formulated composition with ingredients that enhance and maximize each other's healthful properties in a 1: 1 ratio. In other ratios, only the properties of the component with higher concentration begin to dominate.
Trečias pareiškiamo enterosorbento skiriamasis požymis, lyginant su prototipu, yra bendras atrinkto, turinčio 33±1 % anglies šungito ir ceolito smulkinimas vientisame technologiniame cikle. Eksperimentais nustatyta, kad bendras smulkinimas duodą maksimalią mažesnių negu 1 ųm dalelių išeigą ir maksimaliai įmanomą vientisą ZFCS enterosorbento sudėtį, kurios neįmanoma išgauti paprastu atskirai susmulkintų komponentų maišymu. Šiuo atveju sorbuojantys ZFCS komponentai sudaro galingą molekulinį sietą, ant kurio adsorbuojasi nuodai, toksinai, mikroorganizmai, cholesterolis, bilirubinas, šlapalas, serotoninas, histaminas, tulžies rūgštys, radionuklidai, sunkiųjų metalų druskos.The third distinguishing feature of the claimed enterosorbent relative to the prototype is the total crushing of a sample containing 33 ± 1% carbon shungite and zeolite in a single technological cycle. Experiments have shown that total comminution yields a maximum particle yield of less than 1 µm and a maximum possible homogeneous composition of ZFCS enterosorbent, which cannot be obtained by simple mixing of the individually comminuted components. In this case, the sorbing components of ZFCS form a powerful molecular sieve that adsorbs poisons, toxins, microorganisms, cholesterol, bilirubin, urea, serotonin, histamine, bile acids, radionuclides, heavy metal salts.
Žemiau pateikiami išradimo įgyvendinimo galimybę patvirtinantys duomenys. Būdo realizavimas vyko dviem etapais. Pirmajame - atliktas mechaninis šungito uolienų, turinčių 28-32 % anglies, praturtinimas, pagrįstas elektros laidumo naudojimo metodu (E.V.Osipov, S.E.Osipov. Sorbcinis vandens valymo būdas. Patentas LT 5295, paskelbtas OB 2005 m. Nr. 12). Po radiometrinio praturtinimo, svarbiausiojo praktinės vertės požiūriu, indukciniu radijorezonansiniu metodu, skirto gabalinės žaliavos separavimui, buvo atrenkamas šungitas, turintis 33±1 % anglies. Po to tam, kad būtų gautos frakcijos su dalelių dydžiais, mažesniais negu 1 ųm, panaudotas sūkurinio smulkinimo prietaisas. Kaip aprašyta aukščiau, pridedama ceolito ir smulkinama vientisame technologiniame cikle. Magnetiniam separavimui imtos frakcijos su dalelių dydžiais, mažesniais negu 1 pm. Gamybos procese nenaudojami jokie konservantai ir cheminės priemaišos.The data supporting the invention are shown below. The realization of the method took place in two stages. The first involves mechanical enrichment of shungite rocks containing 28-32% carbon based on the electrical conductivity method (E.V.Osipov, S.E.Osipov. A sorption water treatment method. Patent LT 5295, published in OB 2005, No. 12). After radiometric enrichment, for the most important practical value, a shungite containing 33 ± 1% carbon was selected by inductive radio-resonance method for the separation of the bulk material. A vortex shredder was then used to obtain fractions with particle sizes less than 1 µm. As described above, zeolite is added and crushed in a single technological cycle. Fractions with particle sizes less than 1 µm were taken for magnetic separation. The manufacturing process does not use any preservatives or chemical impurities.
Antrame etape gautas enterosorbentas ZFCS pakuojamas į kietas želatinos kapsules (Nr. 0, iki 0,68 ml tūrio, UP „Minskinterkaps“ gamybos), kurios, patenkant per skrandį į organizmą 0,01 g dozėmis 1 kg kūno masės per parą užgeriamos tuo pačiu sorbentu išvalytu vandeniu (E.V.Osipov, S.E.Osipov. Sorbcinis vandens valymo būdas. Patentas LT 5295, paskelbtas OB 2005 m. Nr. 12).The enteric sorbent ZFCS obtained in the second stage is packaged in hard gelatin capsules (No. 0, up to 0.68 ml, produced by UP Minskinterkaps), which are administered at the same dose by the stomach at a dose of 0.01 g / kg / day. sorbent-purified water (EVOsipov, SEOsipov. Sorbent water treatment method. Patent LT 5295, published in OB No. 12, 2005).
Pagaminto entereosorbento ZFCS ir prototipo FCS pagrindinių savybių palyginimui buvo atlikti jų sorbavimo laipsnio matavimai su atominiu-absorbciniu Perkin Elmer 3110 spektrometru, metodo jautrumas lpm/1. Tiriant enterosorbentų ZFCS ir FCS (prototipas) ir kviečių sėlenų (kontrolė) sorbcines savybes, veikiant toksinėms medžiagoms, eksperimentų rezultatai parodė tokį sorbavimo laipsnį (1 lentelė):Measurements of their sorption rate with an atomic-absorbance Perkin Elmer 3110 spectrometer, the sensitivity of the method at lpm / 1, were made to compare the basic properties of the prepared entereosorbent ZFCS and the prototype FCS. The results of the experiments on the sorption properties of enterosorbents ZFCS and FCS (prototype) and wheat bran (control) under the influence of toxic substances showed the following sorption rate (Table 1):
lentelėtable
lentelėje pateikti rezultatai byloja, kad enterosorberit’as ZFCS turi žymiai didesnį sorbcinį aktyvumą toksinių elementų ir aromatinių angliavandenių atžvilgiu, palyginus su FCS prototipu ir kviečių sėlenomis (kontrolė).The results presented in Table 6 demonstrate that enterosorberite ZFCS has significantly higher sorption activity against toxic elements and aromatic carbohydrates compared to the FCS prototype and wheat bran (control).
Enterosorbentas ZFCS turi aukštą adsorbcinį gebėjimą šalinti iš virškinamojo trakto įvairios kilmės endo-, ekzotoksinus ir mikrobus. Masių apykaitoje su sorbentų dalyvauja seilės, skrandžio, plonosios žarnos ir kasos sultys. Enterosorbentas ZFCS iŠ organizmo pasišalina per 24-48 valandas, nesukeldamas vandens-druskų balanso pakitimų, ir gali būti vartojamas botulizmo, maisto ir kitų apsinuodijimų, tarp jų vaistais, alkoholiu, grybais, gydymui.The enterosorbent ZFCS has a high adsorptive ability to eliminate endo-, exotoxins and microbes of various origins from the gastrointestinal tract. Saliva, stomach, small intestine and pancreatic juice are involved in the metabolism with sorbents. The enterosorbent ZFCS is eliminated from the body within 24-48 hours without causing changes in the water-salt balance and can be used to treat botulism, food and other poisonings including drugs, alcohol, fungi.
Be to, enterosorbentas ZFCS turi adaptogeno savybių, todėl gali būti vartojamas profilaktikos tikslais.In addition, the ZFCS enterosorbent has adaptogenic properties and can therefore be used for prophylactic purposes.
Enterosorbentas ZFCS - tai reikalinga mūsų organizmui higiena iš vidaus.Enterosorbent ZFCS - this is what our body needs from the inside.
DOZAVIMAS IR VARTOJIMO BŪDAIDOSAGE AND ROUTE (S) OF ADMINISTRATION
Esant padidintam skrandžio rūgštingumui ZFCS naudoti po vieną kapsulę 1,5 valandos prieš valgį, užgeriant tuo pačiu sorbentų išvalytu vandeniu. Esant normaliam rūgštingumui - 0,5 valandos prieš valgį, užgeriant tuo pačiu sorbentų išvalytu vandeniu. Esant sumažintam rūgštingumui - prieš pat valgį, užgeriant tuo pačiu sorbentų išvalytu vandeniu. Naudoti po 3 kapsules per dieną. Rekomenduojamas kursas - 15 dienų. Naudojant kartu kitus vaistus, intervalas tarp jų ir ZFCS turi būti ne mažiau 1,5-2 valandos.In case of increased gastric acidity use ZFCS one capsule 1.5 hours before meals with the same sorbent purified water. With normal acidity - 0.5 hours before meals, with the same sorbent purified water. With reduced acidity - just before meals, with the same sorbent-treated water. Take 3 capsules a day. Recommended course - 15 days. When used with other drugs, the interval between them and the ZFCS should be at least 1.5-2 hours.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LT2006003A LT5372B (en) | 2006-01-05 | 2006-01-05 | New enterosorbent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LT2006003A LT5372B (en) | 2006-01-05 | 2006-01-05 | New enterosorbent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2006003A LT2006003A (en) | 2006-08-25 |
| LT5372B true LT5372B (en) | 2006-10-25 |
Family
ID=36790698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2006003A LT5372B (en) | 2006-01-05 | 2006-01-05 | New enterosorbent |
Country Status (1)
| Country | Link |
|---|---|
| LT (1) | LT5372B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2390345C2 (en) * | 2006-08-09 | 2010-05-27 | Григорий Моисеевич Шпейзер | Method for extraction of balneologically-active components of mineral waters for drug preparation |
| RU2415704C1 (en) * | 2010-01-11 | 2011-04-10 | Общество с ограниченной ответственностью "ФОСФОРОС" (ООО "ФОСФОРОС") | Method of producing enterosorbent |
-
2006
- 2006-01-05 LT LT2006003A patent/LT5372B/en not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| Retrieved from the Internet <URL:http://argo.5566.ru/bad_litovit.php> |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2390345C2 (en) * | 2006-08-09 | 2010-05-27 | Григорий Моисеевич Шпейзер | Method for extraction of balneologically-active components of mineral waters for drug preparation |
| RU2415704C1 (en) * | 2010-01-11 | 2011-04-10 | Общество с ограниченной ответственностью "ФОСФОРОС" (ООО "ФОСФОРОС") | Method of producing enterosorbent |
Also Published As
| Publication number | Publication date |
|---|---|
| LT2006003A (en) | 2006-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020103432A4 (en) | Method for adsorbing oxytetracycline with cufeo2/bc composite magnetic material | |
| Pavelić et al. | Medical applications of zeolites | |
| Rimoli et al. | Synthetic zeolites as a new tool for drug delivery | |
| CA2542968C (en) | Zeolite molecular sieves for the removal of toxins | |
| JP5707027B2 (en) | Nutritional composition for enhancing antioxidant ability and immunity | |
| Garg et al. | Water remediation using biosorbent obtained from agricultural and fruit waste | |
| CN102274717A (en) | Method for preparing thio-modified sepiolite heavy metal absorbent | |
| CN113456831B (en) | Method for preparing nano-selenium by using eucommia ulmoides polysaccharide and nano-selenium prepared by method | |
| MXPA03006251A (en) | Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages. | |
| CN105962359A (en) | Composition with function of assisting in improving memory | |
| LT5372B (en) | New enterosorbent | |
| EP1369121B1 (en) | Use of zeolites for the preparation of oral compositions for the treatment of poisoning | |
| CN101791123A (en) | Health care product abundant in vitamin B and vitamin C and preparation method thereof | |
| CN1054283C (en) | Ionic skin care powder | |
| KR101748413B1 (en) | Adsorption carbon, and adsorbent | |
| CN102293806A (en) | Method for extracting total flavonoid active part from Huai chrysanthemum and application of total flavonoid active part | |
| US9585913B2 (en) | Clay mineral for reducing inorganic phosphates, in particular in renal replacement therapy | |
| KR20010079473A (en) | as the use of food and drug, Bentonite(or Montmorillonite) containing numerous kinds of colloidal trace minerals | |
| US8758775B2 (en) | Pharmaceutical composition including clinoptilolite | |
| CN101705636B (en) | Nano selenium and germanium chitosan fibre cigarette paper | |
| Göktaş et al. | Clinoptilolite-rich mineral as a novel carrier for the active constituents present in Ginkgo biloba leaf extract | |
| CN112655823A (en) | Clay/amino acid compound additive and preparation method and application thereof | |
| CN1319548C (en) | Chinese medicine health tonic for raising antisenility capacity and improving memory | |
| LT5447B (en) | Novel enterosorbent | |
| Wongtangtintan et al. | Effect of heat treatment on efficacy of Thai bentonite for adsorption of aflatoxin B1 in vitro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 20120105 |